In the BioHarmony Drug Report Database

"Preview" Icon

Luspatercept

Reblozyl (luspatercept) is a protein pharmaceutical. Luspatercept was first approved as Reblozyl on 2019-11-08. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, beta-thalassemia, and myelodysplastic syndromes. It is known to target growth/differentiation factor 11, bone morphogenetic protein 10, growth/differentiation factor 2, growth/differentiation factor 8, and bone morphogenetic protein 6.

 

Trade Name

 

Reblozyl
 

Common Name

 

luspatercept
 

ChEMBL ID

 

CHEMBL3039545
 

Indication

 

anemia, beta-thalassemia, myelodysplastic syndromes
 

Drug Class

 

Receptor molecules, native or modified: transforming growth factor

Image (chem structure or protein)

Luspatercept structure rendering